tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael King, 106 are a BUY (98.15%), 2 are a HOLD (1.85%).
Analyst Michael King, carries an average stock price target met ratio of 41.43% that have a potential upside of 28.13% achieved within 149 days. Previously, Michael King worked at HCWAINWRIGHT.
Michael King’s has documented 205 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on SONN, Sonnet Biotherapeutics Holdings at 23-Aug-2023.
Analyst best performing recommendations are on BMEA (BIOMEA FUSION).
The best stock recommendation documented was for BMEA (BIOMEA FUSION) at 3/24/2023. The price target of $22 was fulfilled within 4 days with a profit of $6.57 (42.58%) receiving and performance score of 106.45.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$338
$28.3 (9.14%)
$328
13 days ago
(12-Jun-2025)
4/6 (66.67%)
$33.33 (10.94%)
7
Buy
$325
$15.3 (4.94%)
$300
1 months 23 days ago
(02-May-2025)
11/12 (91.67%)
$65.61 (25.29%)
270
Hold
$268
$-41.7 (-13.46%)
$284
2 months 14 days ago
(11-Apr-2025)
10/10 (100%)
$30.23 (12.71%)
39
Buy
$320
$10.3 (3.33%)
$320
2 months 16 days ago
(09-Apr-2025)
12/20 (60%)
$76.73 (31.54%)
215
Buy
$500
$190.3 (61.45%)
$500
2 months 23 days ago
(02-Apr-2025)
1/25 (4%)
$233.17 (87.39%)
664
What Year was the first public recommendation made by Michael King?
